Kana Inoue

Ikeda, JP 
Ikeda, JP 

Overview

Kana Inoue practices practicing medicine in Ikeda, Japan.

Their clinical expertise encompasses Pancreatic Cancer, Bunions, Lambert-Eaton Syndrome, and Obesity.

They are actively involved in clinical research, co-authoring 57 peer reviewed articles and participating in 1 clinical trial.

Locations

Ikeda, Japan
Other Locations
Kashiwa, 2778577, Japan
Osaka, Japan
Suita, 5650871, Japan
Asahi, Japan
Chiba, 2610012, Japan
Kumamoto, 8620973, Japan
Kyoto, Japan
Okayama, Japan
Akita, Japan
Kawasaki, Japan
Amagasaki, Japan
Tochigi, Japan
Shinjuku, 1600023, Japan
Nagoya, 4648601, Japan
Sapporo, Japan
Japan
Hachioji, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Enrollment Status: Terminated
Publish Date: January 28, 2026
Intervention Type: Drug
Study Drug: Venglustat GZ402671
Study Phase: Phase 3

57 Total Publications

Intravascular large B-cell lymphoma with reversible central hypopituitarism.
Intravascular large B-cell lymphoma with reversible central hypopituitarism.
Journal: BMJ case reports
Published: September 07, 2026

Frequently Asked Questions about Kana Inoue

Is Kana Inoue a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Kana Inoue is classified as an Experienced expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kana Inoue participate in research or clinical trials?

Yes. Kana Inoue has published 57 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Kana Inoue's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Inoue's expertise for a condition
ConditionClose
        View All 16 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile